Month: August 2020

August 27, 2020, New York/Guangzhou — XPeng Inc. (“XPeng” or the “Company”), a leading Chinese smart electric vehicle (“Smart EV”) company, started trading of its ADSs today at New York Stock Exchange (“NYSE”) under the symbol “XPEV”.  

Centurium Capital RMB Fund I invested in Xpeng in 2017 and held around 3.5% of stake prior to the IPO.

The company priced its IPO of 99,733,334 American Depositary Shares (“ADSs”), each representing two Class A ordinary shares of the Company, at a public offering price of $15.00 per ADS. In addition, XPeng has granted the underwriters a 30-day option to purchase up to an aggregate of 14,959,999 additional ADSs.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by XPeng, will be approximately $1.5 billion, excluding any exercise of the underwriters’ option to purchase additional ADSs.

The offering is expected to close on August 31, 2020, subject to customary closing conditions.

XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future.

In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture.

XPeng is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley, and San Diego in the U.S. and the Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou. For more information, please visit https://en.xiaopeng.com.

August 12, 2020, Beijing – Centurium Capital (“Centurium”), a leading private equity investment firm in China, announced today that it has acquired a controlling stake in Beijing Jingdu Children’s Hospital (“Jingdu”). Located in Changping District in northern Beijing, Jingdu is the largest private children’s hospital in China and the only private tertiary children’s hospital in Beijing.

Launched in June 2015 and located on a 40,000 square meter premises, Jingdu has 36 specialized departments, including an emergency center, and is a recognized leader in children’s hematology, cardiology, dermatology, and stomatology. Jingdu officially became a designated medical institution for Beijing Medical Insurance Plan in 2017.

In July 2020, Jingdu was awarded the Joint Commission International (JCI) accreditation with top marks, becoming the first children’s specialty hospital in China to pass the JCI review via online virtual inspection and evaluation. The JCI accreditation is recognized as a global leader for health care quality and patient safety.

Zhixing Chen, Executive Director of Centurium Capital, commented, “As the largest private tertiary children’s hospital in China, Jingdu has become a leading children’s specialty health services platform, and it has accumulated extensive medical resources and service capabilities. We highly value Jingdu’s brand and professionalism, and firmly believe Jingdu will further solidify its leadership in the industry through continued investment in its medical team and service quality.”

Healthcare is one of the key investment sectors for Centurium. Previously, Centurium has made investments in two other hospitals in China, namely the UIB Group and Beijing Arion Cancer Hospital. Headquartered in Shanghai, UIB Group is a top-tier children and women’s medical services group with a children’s hospital, an obstetrics and gynecology (OBGYN) hospital, and a postpartum center. Arion Cancer Hospital is currently under construction and expected to open by the end of 2020.

Strategically located in the densely-populated Huilongguan-Tiantongyuan area of the Changping District, Jingdu is the only children’s hospital in the district. Driven by its premium medical facilities and services, it treats nearly 300,000 outpatients and 8,000 inpatients a year.

Thanks to its track-record of professionalism and leading research contributions, Jingdu has demonstrated strong business resilience and steady growth despite the impact of Covid-19 pandemic.

We are committed to supporting our portfolio companies to build a robust and transparent corporate governance structure and responsible management system. On 30 July, 2020, we requisitioned Luckin Coffee Inc. (the “Company”) to convene an extraordinary general meeting of members (the “EGM”).

An EGM of the Company was held on 5 July 2020 (the “5 July EGM”), requisitioned by Haode Investment Inc (“Haode”), a company controlled at the time by the former chairman of the Board of Directors of the Company (the “Board”). The timing of the 5 July EGM, the subsequent liquidation process of Haode, and the resolutions proposed by Haode in the 5 July EGM, caused concerns over the independence of the directors nominated by Haode and elected in the 5 July EGM.

It is important that there be no doubt as to the bona fides and ability to exercise independent judgment of any board member in order for the Company to be able to properly function and for the directors to fulfill their fiduciary duties.

Mr Sean Shao had been an independent director and chair of the audit committee of the Company since May 2019, and the chair of the special committee of the Board (the “Special Committee”) since March 2020. In his capacity as the chair of the Special Committee, he led the independent investigation of the Company. He was removed from the Board in the 5 July EGM. His reinstatement will allow for the Board to fully implement the remedial measures as recommended by the Special Committee, and to further facilitate any process related thereto.

The proposed resolutions are necessary actions in order that the Company’s Board can be properly constituted.